Innate Pharma is a biotechnology business based in the US. Innate Pharma shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.24 – an increase of 1.79% over the previous week. Innate Pharma employs 181 staff and has a trailing 12-month revenue of around $20.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.24 |
|---|---|
| 52-week range | $1.29 - $3.51 |
| 50-day moving average | $2.01 |
| 200-day moving average | $2.00 |
| Wall St. target price | $7.84 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.69 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.2393 from 2025-05-05
| 1 week (2025-04-29) | 1.79% |
|---|---|
| 1 month (2025-04-07) | 30.95% |
| 3 months (2025-02-07) | 17.86% |
| 6 months (2024-11-07) | 21.39% |
| 1 year (2024-05-07) | -12.87% |
|---|---|
| 2 years (2023-05-05) | -25.36% |
| 3 years (2022-05-06) | 2.76 |
| 5 years (2020-05-06) | 7.49 |
| Revenue TTM | $20.1 million |
|---|---|
| Gross profit TTM | $-31,859,000 |
| Return on assets TTM | -21.84% |
| Return on equity TTM | -162.91% |
| Profit margin | -245.87% |
| Book value | $0.11 |
| Market Capitalization | $206.4 million |
TTM: trailing 12 months
We're not expecting Innate Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Innate Pharma's shares have ranged in value from as little as $1.29 up to $3.5107. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma's is 0.939. This would suggest that Innate Pharma's shares are less volatile than average (for this exchange).
Innate Pharma S. A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.